HPC Offered for PRESERVE Expansion
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product
| Condition(s) | Bone Marrow Transplant (BMT) |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product |
| Who can participate | Inclusion Criteria: Patients aged 12-80 may be eligible\* to receive bone marrow for transplantation through the Ossium HOPE Program if: Their treating physician determined they are eligible for allogeneic bone marrow transplant Their treating physician determined that the potential benefit outweighs the potential risks |
| Ages | 12 Years to 80 Years |
| Sex | All |
| Lead sponsor | Ossium Health, Inc. |
| Locations | Birmingham, Alabama, United States; Detroit, Michigan, United States; Columbus, Ohio, United States; Nashville, Tennessee, United States |
| Start date | 2024-06-27 |
| NCT ID | NCT07145411 |
| Official listing | https://clinicaltrials.gov/study/NCT07145411 |